<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01191892</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000684016</org_study_id>
    <secondary_id>WCTU-TOUCAN</secondary_id>
    <secondary_id>ISRCTN-68146831</secondary_id>
    <secondary_id>EUDRACT-2009-010140-33</secondary_id>
    <secondary_id>EU-21066</secondary_id>
    <secondary_id>CRUK-09/024</secondary_id>
    <secondary_id>WCTU-SPON-672-09</secondary_id>
    <secondary_id>ZENECA-WCTU-TOUCAN</secondary_id>
    <nct_id>NCT01191892</nct_id>
  </id_info>
  <brief_title>Carboplatin and Gemcitabine Hydrochloride With or Without Vandetanib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urinary Tract Cancer</brief_title>
  <official_title>A Randomized Phase II Trial of Carboplatin and Gemcitabine +/- Vandetanib in First Line Treatment of Advanced Urothelial Cell Cancer in Patients Who Are Not Suitable to Receive Cisplatin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cardiff University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cardiff University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as carboplatin and gemcitabine hydrochloride,&#xD;
      work in different ways to stop the growth of tumor cells, either by killing the cells or by&#xD;
      stopping them from dividing. Vandetanib may stop the growth of tumor cells by blocking some&#xD;
      of the enzymes needed for cell growth and by blocking blood flow to the tumor. It is not yet&#xD;
      known whether giving carboplatin and gemcitabine hydrochloride is more effective with or&#xD;
      without vandetanib as first-line therapy in treating urinary tract cancer.&#xD;
&#xD;
      PURPOSE: This randomized phase II trial is studying giving carboplatin together with&#xD;
      gemcitabine hydrochloride and to see how well it works when given with or without vandetanib&#xD;
      as first-line therapy in treating patients with locally advanced or metastatic urinary tract&#xD;
      cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To determine the antitumor activity (as measured by progression-free survival) of&#xD;
           carboplatin and gemcitabine hydrochloride with versus without vandetanib as first-line&#xD;
           treatment in patients with locally advanced or metastatic urothelial cell cancer who are&#xD;
           not suitable to receive cisplatin.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To determine the safety, feasibility, and tolerability of these regimens in these&#xD;
           patients.&#xD;
&#xD;
        -  To determine the objective response rate.&#xD;
&#xD;
        -  To determine the overall survival of patients treated with these regimens&#xD;
&#xD;
        -  To assess the change of size of measurable lesions at 9 weeks of study therapy.&#xD;
&#xD;
      OUTLINE: This is a multicenter study. Patients are stratified according to relevant factors.&#xD;
      Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive carboplatin IV over 30 minutes on day 1, gemcitabine&#xD;
           hydrochloride IV over 30 minutes on days 1 and 8, and an oral placebo once daily on days&#xD;
           1-21. Treatment repeats every 3 weeks for 6 courses in the absence of disease&#xD;
           progression or unacceptable toxicity.&#xD;
&#xD;
        -  Arm II: Patient receive carboplatin and gemcitabine hydrochloride as in arm I. Patients&#xD;
           also receive oral vandetanib once daily on days 1-21. Treatment repeats every 3 weeks&#xD;
           for 6 courses in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Blood and urine samples may be collected for laboratory analysis at baseline and after&#xD;
      completion of study.&#xD;
&#xD;
      After completion of study treatment, patients are followed up at weeks 18, 26, 39, and 52.&#xD;
&#xD;
      Peer Reviewed and Funded or Endorsed by Cancer Research UK.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">September 5, 2016</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>1 year</time_frame>
    <description>Time to event PFS, follow-up to 1 year</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tolerability and feasibility</measure>
    <time_frame>1 year</time_frame>
    <description>Rate of randomisation and safety profile of randomised patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate as assessed by RECIST criteria</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Proportion of patients responding to treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 years</time_frame>
    <description>Patients will be followed up until death by using NHS flagging service.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in size of measurable lesions 9 weeks after start of chemotherapy</measure>
    <time_frame>9 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity during and after treatment as assessed by NCI CTCAE v 4.0</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">82</enrollment>
  <condition>Bladder Cancer</condition>
  <condition>Transitional Cell Cancer of the Renal Pelvis and Ureter</condition>
  <condition>Ureter Cancer</condition>
  <condition>Urethral Cancer</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Carboplatin, Gemcitabine and Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>vandetanib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Carboplatin, Gemcitabine and vandetanib</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>vandetanib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine hydrochloride</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>vandetanib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vandetanib</intervention_name>
    <arm_group_label>vandetanib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo of vandetanib tablet</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed transitional cell carcinoma (pure or mixed histology) of the&#xD;
             urothelium (upper or lower urinary tract)&#xD;
&#xD;
               -  Cancers with other pathologies are permitted provided the dominant morphology is&#xD;
                  transitional cell carcinoma&#xD;
&#xD;
          -  Radiologically measurable disease according to RECIST v 1.1 criteria&#xD;
&#xD;
          -  Locally advanced and/or metastatic disease not amenable to curative treatment with&#xD;
             surgery or radiotherapy&#xD;
&#xD;
          -  Patient not suitable for cisplatin therapy, meeting 1 or more of the following&#xD;
             criteria:&#xD;
&#xD;
               -  More than 75 years of age&#xD;
&#xD;
               -  ECOG performance status &gt; 2&#xD;
&#xD;
               -  Creatinine clearance &lt; 30 mL/min&#xD;
&#xD;
               -  Clinically significant ischemic heart disease (myocardial infarction or unstable&#xD;
                  angina more than 3 but less than 12 months prior to date of randomization,&#xD;
                  symptomatic angina, or NYHA class I within 3 months prior to date of&#xD;
                  randomization)&#xD;
&#xD;
               -  Prior intolerance of cisplatin&#xD;
&#xD;
               -  Any other factor that, in the opinion of the investigator, indicates that&#xD;
                  cisplatin is not suitable for the patient (e.g., unilateral hearing loss)&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Serum bilirubin ≤ 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Creatinine clearance ≥ 30 mL/min&#xD;
&#xD;
          -  Potassium ≥ 4.0 mmol/L OR below the CTCAE grade 1 upper limit&#xD;
&#xD;
          -  Magnesium normal OR below the CTCAE grade 1 upper limit&#xD;
&#xD;
          -  Serum calcium ≤ 2.9 mmol/L (If serum calcium is &lt; lower limit of normal [LLN], then&#xD;
             adjusted serum calcium must be ≥ LLN)&#xD;
&#xD;
          -  ALT/AST ≤ 2.5 times ULN&#xD;
&#xD;
          -  Alkaline phosphatase ≤ 2.5 times ULN (&lt; 5 times ULN if judged by the investigator to&#xD;
             be related to liver metastases)&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective barrier-method contraception during and for 3&#xD;
             months (women) or 2 months (men) after completion of study therapy&#xD;
&#xD;
          -  No evidence of severe or uncontrolled systemic disease or any concurrent condition&#xD;
             that, in the investigator's opinion, makes it undesirable for the patient to&#xD;
             participate in the trial or that would jeopardize compliance with the protocol&#xD;
&#xD;
          -  No significant risk of cardiac complications, defined as any of the following:&#xD;
&#xD;
               -  Clinically significant cardiovascular event (e.g., myocardial infarction,&#xD;
                  superior vena cava syndrome [SVC], NYHA classification of heart disease ≥ class&#xD;
                  II within 3 months prior to entry, or presence of cardiac disease that, in the&#xD;
                  opinion of the investigator, significantly increases the risk of ventricular&#xD;
                  arrhythmia)&#xD;
&#xD;
               -  History of arrhythmia (multifocal premature ventricular contractions, bigeminy,&#xD;
                  trigeminy, ventricular tachycardia, or uncontrolled atrial fibrillation) that is&#xD;
                  symptomatic or requires treatment (CTCAE grade 3) or asymptomatic sustained&#xD;
                  ventricular tachycardia&#xD;
&#xD;
                    -  Atrial fibrillation, controlled on medication, is not exclusionary&#xD;
&#xD;
          -  No QTc prolongation with other medications that requires discontinuation of that&#xD;
             medication&#xD;
&#xD;
          -  No congenital long QT syndrome or first-degree relative with unexplained sudden death&#xD;
             under 40 years of age&#xD;
&#xD;
          -  No QTc that is immeasurable or ≥ 480 msec on screening ECG&#xD;
&#xD;
               -  If a patient has a QTc interval ≥ 480 msec on screening ECG, the ECG screen may&#xD;
                  be repeated twice (at least 24 hours apart) and the average QTc from the three&#xD;
                  screening ECGs must be &lt; 480 msec in order for the patient to be eligible for the&#xD;
                  study&#xD;
&#xD;
               -  Patients who are receiving a drug that has a risk of Torsades de Pointes are&#xD;
                  excluded if QTc is ≥ 460 msec&#xD;
&#xD;
          -  No presence of left bundle branch block&#xD;
&#xD;
          -  No hypertension not controlled by medical therapy (systolic blood pressure &gt; 160 mm Hg&#xD;
             or diastolic blood pressure &gt; 100 mm Hg)&#xD;
&#xD;
          -  No currently active diarrhea that, in the investigator's opinion, may affect the&#xD;
             ability of the patient to either absorb vandetanib or to tolerate additional diarrhea&#xD;
             episodes&#xD;
&#xD;
          -  No previous or current malignancies of other histology within the past 5 years except&#xD;
             for carcinoma in situ of the cervix, adequately treated basal cell or squamous cell&#xD;
             carcinoma of the skin, or prostate cancer&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 2 weeks since prior and no concurrent known potent CYP3A4 inducers (e.g.,&#xD;
             barbiturates, rifampicin, rifabutin, phenytoin, carbamazepine, troglitazone,&#xD;
             phenobarbital, or St. John wort) or medication that has known adverse interactions&#xD;
             with vandetanib&#xD;
&#xD;
               -  Dexamethasone (or equivalent) allowed as a pre-medication for chemotherapy&#xD;
&#xD;
          -  At least 4 weeks since prior major surgery and complete surgical wound healing&#xD;
&#xD;
          -  At least 30 days since prior and no other concurrent investigational agents&#xD;
&#xD;
          -  No prior chemotherapy (unless delivered perioperatively and completed &gt; 12 months&#xD;
             prior to first presentation of recurrent disease)&#xD;
&#xD;
          -  No other concurrent anticancer drug&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Jones, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Glasgow</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beatson West of Scotland Cancer Centre</name>
      <address>
        <city>Glasgow</city>
        <state>Scotland</state>
        <zip>G12 0YN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wales Cancer Trials Unit</name>
      <address>
        <city>Cardiff</city>
        <state>Wales</state>
        <zip>CF11 9LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ayr Hospital</name>
      <address>
        <city>Ayr</city>
        <zip>KA66DX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Bournemouth General Hospital</name>
      <address>
        <city>Bournemouth</city>
        <zip>BH7 7DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queens Hospital</name>
      <address>
        <city>Burton upon Trent</city>
        <zip>DE13 0RB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Velindre Hospital</name>
      <address>
        <city>City And County Of Cardiff</city>
        <zip>CF142TL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western General Hospital</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH4 2XU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Calderdale Royal Infirmary</name>
      <address>
        <city>Halifax</city>
        <zip>HX30PW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Huddersfield Royal Infirmary</name>
      <address>
        <city>Huddersfield</city>
        <zip>HD3 3EA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Royal Lancaster Infirmary</name>
      <address>
        <city>Lancaster</city>
        <zip>LA1 4RP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. James's University Hospital</name>
      <address>
        <city>Leeds</city>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Royal Free Hospital</name>
      <address>
        <city>London</city>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Marys Hospital</name>
      <address>
        <city>London</city>
        <zip>W21NY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charing Cross Hospital</name>
      <address>
        <city>London</city>
        <zip>W68RF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christie Hospital</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Vernon Hospital</name>
      <address>
        <city>Northwood Middlesex</city>
        <zip>HA6 2RN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Churchill Hospital</name>
      <address>
        <city>Oxford</city>
        <zip>OX37LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weston Park Hospital</name>
      <address>
        <city>Sheffield</city>
        <zip>S102SJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southampton General Hospital</name>
      <address>
        <city>Southampton</city>
        <zip>S016 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Surrey County Hospital</name>
      <address>
        <city>Surrey</city>
        <zip>GU27XX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Royal Marsden Hospital</name>
      <address>
        <city>Surrey</city>
        <zip>KT2 7QB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>August 29, 2010</study_first_submitted>
  <study_first_submitted_qc>August 29, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2010</study_first_posted>
  <last_update_submitted>May 14, 2019</last_update_submitted>
  <last_update_submitted_qc>May 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>metastatic transitional cell cancer of the renal pelvis and ureter</keyword>
  <keyword>regional transitional cell cancer of the renal pelvis and ureter</keyword>
  <keyword>transitional cell carcinoma of the bladder</keyword>
  <keyword>stage III bladder cancer</keyword>
  <keyword>stage IV bladder cancer</keyword>
  <keyword>anterior urethral cancer</keyword>
  <keyword>posterior urethral cancer</keyword>
  <keyword>urethral cancer associated with invasive bladder cancer</keyword>
  <keyword>ureter cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
    <mesh_term>Urethral Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
    <mesh_term>Kidney Neoplasms</mesh_term>
    <mesh_term>Ureteral Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

